Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.08 · Revenue $500000.00 · 1 analysts
Est. EPS $-0.06 · Revenue $1.00M · 1 analysts
Est. EPS $-0.28 · Revenue $1.50M · 1 analysts
EPS $-0.17 · Revenue $0.00
EPS $-0.07 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-10.4M | +37.0% | -73.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-3.7M | +27.3% | +42.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 8.0% | -44.9% | -100.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.14x | +164.4% | +130.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $7.3M | +454.5% | -7.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.33 vs -0.31 | -6.5% | -1.39 vs -0.07 | -1885.7% |
| Revenue Surprise | $0 vs $1.5B | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Mushak Andriy | officer | — | — | 0 | — |
| May 21, 2026 | Aminov Erez | director, officer: CEO and Chairman | Non-Qualified Stock Options (right to buy) | A | 2,000,000 | $1.30 |
| May 21, 2026 | Aminov Erez | director, officer: CEO and Chairman | Incentive Stock Options (right to buy) | A | 1,960,170 | $1.30 |
| May 21, 2026 | Aminov Erez | director, officer: CEO and Chairman | Incentive Stock Options (right to buy) | D | 1,960,170 | $5.02 |
| May 21, 2026 | Aminov Erez | director, officer: CEO and Chairman | Non-Qualified Stock Options (right to buy) | D | 2,000,000 | $2.10 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Erez Aminov | Chairman of the Board & Chief Executive Officer | USD 296,350 | Male | 1978 | Active |
Alan Weichselbaum | Chief Financial Officer | USD 59,200 | Male | 1965 | Active |
Andriy Mushak | Chief Financial Officer | USD 59,200 | Male | 1983 | Active |
Itzchak Angel | Chief Scientific Advisor | — | — | — | Active |
Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday. The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at
Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).
